# US 11,895,992 B2 · Animal models of corneal ectatic diseases, methods of producing, and methods of use thereof

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 11,895,992 B2
- Document ID: US11895992B2
- Status: Granted
- Kind: B2
- Application number: 16/538,334
- Filed: 2019-08-12
- Published: 2019-11-28
- Granted: 2024-02-13
- Earliest claimed: 2014-06-03
- Applicants: Arturo Solis Herrera
- Inventors: Arturo Solis Herrera
- Web page: https://patentgrep.com/patent/US11895992B2

## CPC

- A01K 67/027: New or modified breeds of vertebrates
- A61K 31/03: aromatic
- A61K 31/05: Phenols {(cannabinoids A61K31/658)}
- A61K 49/0008: {Screening agents using (non-human) animal models or transgenic animal models or chimeric hosts, e.g. Alzheimer disease animal model, transgenic model for heart failure}
- A61P 27/02: Ophthalmic agents
- A01K 2227/10: Mammal
- A01K 2267/035: Animal model for multifactorial diseases
- A01K: ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

Methods of producing non-human animal models of corneal ectatic diseases, such as corneal keratoconus, by applying an aromatic compound to the eye of a non-human animal are described. Also described are non-human animal models of corneal ectatic diseases, and methods of using the non-human animal models to screen compounds that modulate corneal ectatic diseases.

## Claims

### Claim 1

A method of producing a non-human animal model of a corneal ectatic disease, the method comprising applying to a cornea of at least one eye of a non-human animal an effective amount of an aromatic compound selected from the group consisting of benzene and phenol, wherein the effective amount of benzene applied is 70 μmol to 85 μmol and the effective amount of phenol applied is 30 μmol to 70 μmol.

### Claim 2 (depends on 1)

The method of claim 1, wherein the aromatic compound is applied as an aqueous vehicle.

### Claim 3 (depends on 1)

The method of claim 1, wherein the corneal ectatic disease is corneal keratoconus.

### Claim 4 (depends on 1)

A non-human animal model of a corneal ectatic disease prepared by the method of claim 1.

### Claim 5 (depends on 4)

The non-human animal model of claim 4, wherein the cornea of the at least one eye one eye comprises a structural distortion characterized as a change in shape from a rounded shape to a conical shape.

### Claim 6

A method of screening compounds to modulate a corneal ectatic disease, the method comprising:
(i) preparing a non-human animal model of a corneal ectatic disease by a method comprising applying to a cornea of at least one eye of a non-human animal an effective amount of an aromatic compound selected from the group consisting of benzene and phenol, wherein the effective amount of benzene applied is 70 μmol to 85 μmol and the effective amount of phenol applied is 30 μmol to 70 μmol;
(ii) administering a test compound to the at least one eye of the non-human animal model; and
(iii) determining an effect of the test compound on structural distortion of the cornea.

### Claim 7 (depends on 6)

The method of claim 6, wherein the test compound is administered to the at least one eye prior to, simultaneously with, or after application of the aromatic compound.

### Claim 8 (depends on 6)

The method of claim 6, wherein the corneal ectatic disease is corneal keratoconus.